Introduction Pancreas ductal adenocarcinoma (PDAC) is a frequently lethal malignancy that
poses unique therapeutic challenges. The current mainstay of therapy for metastatic PDAC …

The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple
cancers and has bolstered interest in this treatment approach. So far, emerging clinical data …

Prostate cancer is one of the most common malignant cancers of the male genitourinary
system and has high morbidity and mortality. Currently, treatment modalities for localized …

The advent of polyadenosine diphosphate ribose polymerase inhibitors (PARPi) has
brought about significant changes in the field of ovarian cancer treatment. However, in 2022 …

ABSTRACT PARP inhibitors are synthetically lethal with BRCA1/2 mutations, and in this
setting, accumulation of DNA damage leads to cell death. Because increased DNA damage …

Background High grade serous ovarian cancer (HGSOC) is among the deadliest human
cancers and its prognosis remains extremely poor. Tumor heterogeneity and rapid …

Background Despite standard treatment for epithelial ovarian cancer (EOC), that involves
cytoreductive surgery followed by platinum-based chemotherapy, and initial high response …

Abstract Poly (ADP-ribose) polymerase (PARP), which was first described over 50 years ago
by Mandel, are a family of protein enzymes involved in DNA damage response and works by …

Breast cancer (BC) has a high mortality rate and is one of the most common malignancies in
the world. Initially, BC was considered non-immunogenic, but a paradigm shift occurred with …

The year 2019 witnessed the first approval of an immune checkpoint inhibitor (ICI) for the
management of triple negative breast cancers (TNBC) that are metastatic and programmed …